Articles On Respiri (ASX:RSH)

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Summary Drug development and clinical services company Emyria has obtained Class IIa TGA registration for its medical-grade monitoring tool, Openly. With this TGA registration, Emyria is in a leading position to develop Real World Evid...

The ASX had a solid start to the week, gaining over 1 per cent and hitting a record high. The ASX 200 closed 1.3 per cent up at 7,172.8 which is a record closing high although not quite an all-time intra day high. The #ASX 200 rose by 92pt...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Last year's pandemic put the focus firmly on telehealth services providers, but share prices have deflated since as investors started asking questions, and on the general realisation telehealth has its limits too. -Covid-19 triggered a rush...

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...

The Respiri Ltd Fully Paid Ord. Shrs (ASX: RSH) share price has rocketed 18.2% higher at the market open after an update from the Aussie medical device company. Why is the Respiri share price on the charge? Respiri this morning announced a...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Wall Street mixed as iron ore climbs to record high Wall Street moved modestly overnight. The Dow Jones gained 0.01%, S&P500 lost 0.02%, while tech heavy NASDAQ also fell by 0.34%. Tesla was the biggest name to fall, dropping 4.5%, as y...

Summary With the current emergency, it is anticipated that telehealth or telemedicine could be the future of medicine. COVID-19 pandemic resulted in considerable adoption of telehealth solutions, mainly to avoid physical contact. The...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

This tiny MedTech company, Respiri Ltd [ASX:RSH] managed to quadruple its share price from a low 6 cents in March to around 24 cents in mid-October... The post Are Respiri Shares Set for Another Breakout? (ASX:RSH) appeared first on Money M...

Respiratory health technology company Respiri (ASX: RSH) is trialling a telehealth and remote patient management program in Australia that will also form the basis of the model for the US reimbursement market. Led by leading respiratory phy...

The company’s flagship product Wheezo has received US FDA clearance, with a UK launch scheduled for the end of the year. eHealth MedTech company, Respiri (ASX:RSH), has appointed strategic advisors in Australia and the UK, as part of its pl...

Days after obtaining Food and Drug Administration approval for sales of its wheezo device in the US, Respiri (ASX: RSH) has progressed its international expansion plans with strategic adviser appointments to assist with preparing a UK marke...

Respiri Ltd (ASX: RSH) shares were on the move this morning after the company announced it will be launching its Wheezo brand in the United Kingdom. The Respiri share price opened around 3% higher following the news. However, at the time o...

According to CEO Marjan Mikel, “The regulatory clearance of wheezo and our App in the United States represents a highly significant and major milestone for the company as we continue to expand our regulatory footprint for wheezo and...

Global stock markets dipped Stock markets dipped globally on fears over a potential third lockdown in Europe. Wall Street has seesawed throughout the week, as European shares hit a two-week low. Dow Jones was down 0.01%, S&P 500 fell by...

Respiri (ASX:RSH) has just achieved a huge corporate milestone: its wheeze-detecting device has been approved for sale in the United States, an asthma market that dwarfs any other in the world. Respiri’s wheezo was granted 510(k) clearance...

Source: create jobs 51, Shutterstock Summary MGC Pharmaceuticals has received approval from the Ethics Committee for Phase 3 clinical trial of CimetrATM in COVID-19 patients. eHealth SaaS player Respiri Limited has obtained US FDA’s a...

Wheezo device and app technology developer, Respiri (ASX: RSH) has received the greenlight from the United States Food and Drug Administration (FDA) to market and sell the technology as a class II medical device in the country. The regulato...

The Respiri Ltd (ASX: RSH) share price is on watch today after the company advised it has received United States Food and Drug Administration (FDA) clearance for its Wheezo app.  About Respiri   Respiri is a software-as-a-service (SaaS) co...

Small caps have dipped slightly, while their larger peers have gained. The Small Ordinaries index fell 2.6 points on Monday, or 0.08 per cent, to 3,195.6, while the ASX100 gained 0.73 per cent and the All Ordinaries gained 0.51 per cent. Th...

Small caps have closed lower today, but they finished the week in the green for a second week in a row. The Small Ordinaries index dropped 16.9 points, or 0.5 per cent, on Friday, doing slightly better than their larger peers. The ASX100 fi...

Source: mstanley, Shutterstock On Friday, the market opened lower however, the bulls managed to push the market from the lows to an extent up to the lunch session. However, the selling pressure seeped in and the market declined  towards th...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Special Report: Asthma is the fourth most-prevalent non-communicable disease in the world, killing an estimated 400 Australians each year and ... Read More The post Asthma costs Australia $28 billion a year. Respiri wants to change that. ap...

Respiri (ASX:RSH) is taking a big step forward with an agreement for its Pharmacy Catalyst members to sell its wheezo ... Read More The post Pharmacists to begin recommending Respiri’s wheezo asthma management device appeared first on Stock...

Summary Respiri Limited announced that Pharmacy Catalyst members to provide support to sales of wheezo with the in-pharmacy asthma management program. The Company would continue to introduce the program across several other members pha...

Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and platform after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy asthma patient program next month. Pharma...

Zip Co Ltd (ASX: Z1P) shares struggled in the second half of 2020 despite the company’s strong growth performance and positive announcements. With everything that’s going for the buy now, pay later (BNPL) company, why has the Zip share pri...

Special Report: Respiratory health company Respiri has entered into a sales and marketing partnership for its wheezo devices for asthma ... Read More The post Respiri rolls out wheezo device distribution with Pharmacy 4 Less group appeared...

Respiratory health technology company Respiri (ASX: RSH) has announced a new sales and marketing partnership with the Pharmacy 4 Less group for the sale of its asthma management device wheezo commencing early next year. This is the second p...

Immutep Limited (ASX: IMM) announced that its Chinese partner, EOC Pharma, will begin a new Phase II clinical trial on up to 152 metastatic breast cancer patients in China. Immutep Limited is a biotechnology company, which develops novel i...

Special Report: Respiri’s deal with Cipla will allow it to boost distribution of its wheezo asthma management device via direct ... Read More The post Respiri reasserts full-year revenue guidance after locking in key product order, shares c...

Demand for Respiri’s (ASX: RSH) wheezo asthma management device has continued to grow following the platform’s recent commercial launch in Australia with sales orders increasing and a new banner partnership announced. The respiratory health...

Summary Despite the challenges imposed by COVID-19, Volpara Heath delivered a substantial 38% revenue growth. Metrics such as gross margin and group ARPU also improved over the previous corresponding period. In 2H FY2021, Volpara would...

Three months after announcing the start of a co-major partnership with Carlton Football Club, health technology developer Respiri (ASX: RSH) has revealed its product logo will adorn the club’s official women’s uniform and training gear next...

It’s been a bumpy road of development for Respiri Ltd [ASX:RSH]. Today though, with an early gain of 12.9%, The RSH share price seems to be heading back in the right direction. So, what was behind the turnaround? The post Respiri Reports Re...

With Respiri’s (ASX: RSH) stage launch of wheezo across select Australian pharmacies and online underway, the company has revealed further major cost reductions resulting in improved margins. The cost reductions are a result of “significant...

Special Report: Respiri Limited’s (ASX:RSH) expects its gross product margins for its wheezos to be 30 per cent higher than ... Read More The post Respiri details ‘exceptional’ cost savings to wheezo production appeared first on Stockhead.

Respiratory health management company Respiri (ASX: RSH) has updated the market regarding the preliminary release of its wheezo platform and device, saying it was “very pleased” with the responses it has received from pharmacists and partne...

Summary ASX-listed eHealth SaaS Company Respiri Limited filed for an additional patent application for asthma management device- wheezo. The additional patent filing was based on advancements made to the wheezo™ algorithm during the pre...

Respiratory-focused eHealth company Respiri (ASX: RSH) has filed an additional patent application based on recent improvements made to the algorithm for its wheezo asthma management device. The new intellectual property relates principally...

Special Report: Melbourne-based asthma assessment company Respiri is taking steps to protect its commercial advantage before its Australian launch with ... Read More The post Respiri takes steps to secure intellectual property with another...

Openpay Group Ltd (ASX: OPY) has achieved record growth in the first quarter of FY21, potentially opening the way for the Openpay share price to reverse the losses over the past month. This includes increases in active customers by 145% an...

Special Report: Respiri Limited has completed an oversubscribed $12.5 million to fund the launch of its wheezo asthma management device. ... Read More The post Investors line up to give Respiri cash as wheezo launches into Australian pharma...

Summary Respiri Limited announced the successful completion of a $12.5 million share placement. The Company would issue 62.5 million shares at $0.20 per share at a healthy discount of 6.5% to the VWAP of the last 30 days. Proceeds from...

eHealth company Respiri (ASX: RSH) has completed a $12.5 million capital raising targeted at the commercial launch of its proprietary wheezo asthma management platform in Australia before year end. The raising was conducted via the issue of...